Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study-Reference-Cited by-同舟云学术

Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study

Published:2013-02 Issue:2 Volume:31 Page:180-186
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Caffo Orazio,Fratino Lucia,Barbieri Roberto,Perin Alessandra,Martini Thomas,Sava Teodoro,Segati Romana,Vaccher Emanuela,Bernardo Bassan Franco,Veccia Antonello,Pappagallo Giovanni,Galligioni Enzo

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference42 articles.

1. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points;Tannock;J Clin Oncol,1996

2. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study;Kantoff;J Clin Oncol,1999

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current therapy and drug resistance in metastatic castration-resistant prostate cancer;Drug Resistance Updates;2023-05

2. Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer;OncoTargets and Therapy;2018-05

3. Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems;Acta Pharmaceutica;2016-03-01